Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform

TLDR Tempus AI total contract value exceeded $1.1 billion, marking highest level in company history Company signed 70 data agreements with pharmaceutical companies including Pfizer, Merck, and AstraZeneca Diagnostics revenue grew 111% to $955 million with oncology testing up 26% Data and Applications segment revenue reached $316 million, up 31% year-over-year Wall Street consensus rating [...]

The post Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform appeared first on Blockonomi.